Bioquicknews Transcript des WallStreetReporter Calls:
www.bioquicknews.com/node/5315
Bullet Points from the Call to remember:
QUESTION 8
“What are the two most significant challenges your company leadership faces in the next four months”
ANSWER—DR. POURHASSAN “Manufacturing, manufacturing, and manufacturing. [28:48] We have a solution to the world, we potentially have. We’re waiting in desperate, desperate days. These are very valuable days we are waiting and I have gotten hold of Dr. xxxxx at Samsung. That’s the only company that can produce whatever we need. AGC is not capable of producing that kind of volume, but they’re doing a good job giving us the small volumes. But we could get 1.2 million doses this year and I have heard that Gilead is prepared for 130,000 patients, and to get any more from them will have to wait until next year.” “So, we’re ahead of them. We’re way ahead of them, because we could have 1.2 million if not more, but we need to get funding to get Samsung to expedite everything. And I’m not able to use shareholder value because the company doesn’t belong to me, it belongs to the shareholders, and we don’t want to dilute the company because that’s not what our shareholders want. So, we need the government to help us…… work with the data.” [29:57]
QUESTION 13 “Nasdaq listing timeline?” (a number of questions about this)
ANSWER—DR. POURHASSAN “Nasdaq has a number of criteria. We meet most of the criteria, but we don’t meet is the equity value of $5 million by raising funds based upon the last 4 quarters we spent is about $55 million or so. So, now we have a decision to make—do we want to do xxxxx and be able to up-list or do we want to xxxx we need to authorize more shares [xxxxx] we don’t want to dilute the company the way it was diluted before that, under different leadership. And 100 million shares were authorized and the [xxxx] was very bad news for us make that decision, we want to wait a little bit—see how our trials come out and how the stock price comes up. If the stock price goes to double-digit ….. the main criteria.” (Double-check this paragraph) “The other criteria we need to be very careful about is do we have the share price above $3 for several days in a row. Over $2 [xxxxx]” “So, all those criteria have been met, but the fund-raising. I want all the shareholders to know that if they exercise their warrants, then we will have enough funds without diluting the company…. to offer this to New York or to Nasdaq, I believe.” [39:46]
CytoDyn $CYDY mit Blockbuster Potential WKN: A0YHA5 | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1...g_63567879
www.bioquicknews.com/node/5315
Bullet Points from the Call to remember:
QUESTION 8
“What are the two most significant challenges your company leadership faces in the next four months”
ANSWER—DR. POURHASSAN “Manufacturing, manufacturing, and manufacturing. [28:48] We have a solution to the world, we potentially have. We’re waiting in desperate, desperate days. These are very valuable days we are waiting and I have gotten hold of Dr. xxxxx at Samsung. That’s the only company that can produce whatever we need. AGC is not capable of producing that kind of volume, but they’re doing a good job giving us the small volumes. But we could get 1.2 million doses this year and I have heard that Gilead is prepared for 130,000 patients, and to get any more from them will have to wait until next year.” “So, we’re ahead of them. We’re way ahead of them, because we could have 1.2 million if not more, but we need to get funding to get Samsung to expedite everything. And I’m not able to use shareholder value because the company doesn’t belong to me, it belongs to the shareholders, and we don’t want to dilute the company because that’s not what our shareholders want. So, we need the government to help us…… work with the data.” [29:57]
QUESTION 13 “Nasdaq listing timeline?” (a number of questions about this)
ANSWER—DR. POURHASSAN “Nasdaq has a number of criteria. We meet most of the criteria, but we don’t meet is the equity value of $5 million by raising funds based upon the last 4 quarters we spent is about $55 million or so. So, now we have a decision to make—do we want to do xxxxx and be able to up-list or do we want to xxxx we need to authorize more shares [xxxxx] we don’t want to dilute the company the way it was diluted before that, under different leadership. And 100 million shares were authorized and the [xxxx] was very bad news for us make that decision, we want to wait a little bit—see how our trials come out and how the stock price comes up. If the stock price goes to double-digit ….. the main criteria.” (Double-check this paragraph) “The other criteria we need to be very careful about is do we have the share price above $3 for several days in a row. Over $2 [xxxxx]” “So, all those criteria have been met, but the fund-raising. I want all the shareholders to know that if they exercise their warrants, then we will have enough funds without diluting the company…. to offer this to New York or to Nasdaq, I believe.” [39:46]
CytoDyn $CYDY mit Blockbuster Potential WKN: A0YHA5 | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1...g_63567879
